Compare Eni SpA (E) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Eni SpA trades at $58.97 (market cap $82.04B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Eni SpA is far larger — about 84.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Eni SpA pays a 4.25% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| E | MRVI | |
|---|---|---|
Market Cap | $82.04B | $972.90M |
Volume | 245,093 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $57.71 | $9.00 |
52-Week Low | $34.20 | $2.83 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $106.48B | $1.08B |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $57.71, up 1.66% today, with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 13.35 and P/S of 0.88, though recent earnings missed expectations in Q1 and Q2 2026. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, but net income margin improved to 5.97% in 2026 projections. Recent developments include expansion in Venezuela oil opportunities and humanoid robotics partnerships.
The outlook remains cautiously optimistic with 34.6% analyst buy ratings and improving profitability margins. Key opportunities include Venezuela oil expansion and cost discipline, while risks involve revenue volatility and execution challenges. The stock presents value characteristics with reasonable valuation, though investors should monitor earnings consistency and global energy market conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
